These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 18018814)

  • 1. Abuse of buprenorphine in the United States: 2003-2005.
    Smith MY; Bailey JE; Woody GE; Kleber HD
    J Addict Dis; 2007; 26(3):107-11. PubMed ID: 18018814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abuse and diversion of buprenorphine sublingual tablets and film.
    Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
    J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A naturalistic comparison of the effectiveness of methadone and two sublingual formulations of buprenorphine on maintenance treatment outcomes: findings from a retrospective multisite study.
    Proctor SL; Copeland AL; Kopak AM; Herschman PL; Polukhina N
    Exp Clin Psychopharmacol; 2014 Oct; 22(5):424-33. PubMed ID: 25069011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversion and abuse of buprenorphine: findings from national surveys of treatment patients and physicians.
    Johanson CE; Arfken CL; di Menza S; Schuster CR
    Drug Alcohol Depend; 2012 Jan; 120(1-3):190-5. PubMed ID: 21862241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of buprenorphine in the Veterans Health Administration: results of the first 3 years.
    Gordon AJ; Trafton JA; Saxon AJ; Gifford AL; Goodman F; Calabrese VS; McNicholas L; Liberto J;
    Drug Alcohol Depend; 2007 Oct; 90(2-3):292-6. PubMed ID: 17493771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability.
    Koch AL; Arfken CL; Schuster CR
    Drug Alcohol Depend; 2006 Jul; 83(3):274-8. PubMed ID: 16413146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
    Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
    J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users.
    Alho H; Sinclair D; Vuori E; Holopainen A
    Drug Alcohol Depend; 2007 Apr; 88(1):75-8. PubMed ID: 17055191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
    Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
    J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres.
    Leonardi C; Hanna N; Laurenzi P; Fagetti R;
    Drug Alcohol Depend; 2008 Apr; 94(1-3):125-32. PubMed ID: 18162330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence of childhood trauma among those seeking buprenorphine treatment.
    Sansone RA; Whitecar P; Wiederman MW
    J Addict Dis; 2009; 28(1):64-7. PubMed ID: 19197597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.
    Lavie E; Fatséas M; Denis C; Auriacombe M
    Drug Alcohol Depend; 2009 Jan; 99(1-3):338-44. PubMed ID: 18824311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
    Compton P; Ling W; Moody D; Chiang N
    Drug Alcohol Depend; 2006 Mar; 82(1):25-31. PubMed ID: 16144748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
    Cicero TJ; Surratt H; Inciardi JA; Munoz A
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Public policy statement on buprenorphine for opiate dependence and withdrawal.
    J Addict Dis; 2003; 22(3):113-4. PubMed ID: 14621350
    [No Abstract]   [Full Text] [Related]  

  • 20. [Maintenance treatment for opioid dependence in care centers: the OPPIDUM program of the Evaluation and Information Centers for Drug Addiction].
    Thirion X; Barrau K; Micallef J; Haramburu F; Lowenstein W; Sanmarco JL
    Ann Med Interne (Paris); 2000 Apr; 151 Suppl A():A10-7. PubMed ID: 10855372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.